메뉴 건너뛰기




Volumn 99, Issue , 2016, Pages 117-119

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung

Author keywords

Drug induced myocarditis; Immunotherapy; Nivolumab; PDL 1; Pulmonary squamous cell carcinoma

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CISPLATIN; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GADOLINIUM; NAVELBINE; NIVOLUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 LIGAND 1; TROPONIN T; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 84978821866     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.025     Document Type: Article
Times cited : (85)

References (15)
  • 1
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    • [1] Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
    • (2002) Nat. Med. , vol.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3
  • 2
    • 0037126021 scopus 로고    scopus 로고
    • Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    • [2] Iwai, Y., Ishida, M., Tanaka, Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99:19 (2002), 12293–12297.
    • (2002) Proc. Natl. Acad. Sci. U.S.A. , vol.99 , Issue.19 , pp. 12293-12297
    • Iwai, Y.1    Ishida, M.2    Tanaka, Y.3
  • 3
    • 84859158384 scopus 로고    scopus 로고
    • Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    • [3] Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24 (2012), 207–212.
    • (2012) Curr. Opin. Immunol. , vol.24 , pp. 207-212
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 4
    • 84924901863 scopus 로고    scopus 로고
    • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
    • [4] Rizvi, N.A., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 3 (2015), 257–265.
    • (2015) Lancet Oncol. , vol.3 , pp. 257-265
    • Rizvi, N.A.1
  • 5
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • [5] Brahmer, J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:2 (2015), 123–135.
    • (2015) N. Engl. J. Med. , vol.373 , Issue.2 , pp. 123-135
    • Brahmer, J.1
  • 6
    • 84936749833 scopus 로고    scopus 로고
    • Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
    • [6] Gettinger, S.N., et al. Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J. Clin. Oncol. 33 (2015), 2004–2012.
    • (2015) J. Clin. Oncol. , vol.33 , pp. 2004-2012
    • Gettinger, S.N.1
  • 7
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti–PD-L1 antibody in patients with advanced cancer
    • [7] Brahmer, J., et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
    • (2012) N. Engl. J. Med. , vol.366 , pp. 2455-2465
    • Brahmer, J.1
  • 8
    • 84958181736 scopus 로고    scopus 로고
    • Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
    • [8] Villadolid, J., Asim, A., Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4:5 (2015), 560–575.
    • (2015) Transl. Lung Cancer Res. , vol.4 , Issue.5 , pp. 560-575
    • Villadolid, J.1    Asim, A.2
  • 9
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • [9] Topalian, S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
    • (2014) J. Clin. Oncol. , vol.32 , pp. 1020-1030
    • Topalian, S.L.1
  • 10
    • 77954019731 scopus 로고    scopus 로고
    • PD-1 deficiency results in the development of fatal myocarditis in MRL mice
    • [10] Wang, J., Okazaki, I.M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22 (2010), 443–452.
    • (2010) Int. Immunol. , vol.22 , pp. 443-452
    • Wang, J.1    Okazaki, I.M.2    Yoshida, T.3    Chikuma, S.4    Kato, Y.5    Nakaki, F.6
  • 11
    • 84997637224 scopus 로고    scopus 로고
    • Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
    • [11] Läubli, H., et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer, 3, 2015, 11.
    • (2015) J. Immunother. Cancer , vol.3 , pp. 11
    • Läubli, H.1
  • 12
    • 84922392615 scopus 로고    scopus 로고
    • Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance
    • [12] Jordan, J.H., et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging 7:November (6) (2014), 872–879.
    • (2014) Circ. Cardiovasc. Imaging , vol.7 , Issue.November (6) , pp. 872-879
    • Jordan, J.H.1
  • 13
    • 40949103615 scopus 로고    scopus 로고
    • Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
    • [13] Fallah-Rad, N., et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J. Cardiovasc. Magn. Reson., 10, 2008, 5.
    • (2008) J. Cardiovasc. Magn. Reson. , vol.10 , pp. 5
    • Fallah-Rad, N.1
  • 14
    • 84973281958 scopus 로고    scopus 로고
    • Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
    • (Feb 21 [Epub ahead of print])
    • [14] Gulati, G., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J., 2016 (Feb 21 [Epub ahead of print]).
    • (2016) Eur. Heart J.
    • Gulati, G.1
  • 15
    • 84939227614 scopus 로고    scopus 로고
    • Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of Programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers
    • [15] Carbognin, L., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of Programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 6, 2015, e0130142.
    • (2015) PLoS One , vol.6 , pp. e0130142
    • Carbognin, L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.